|
|
 |
|
Viewing report
|
|
|
|
Provenge fails to Live up to Dendreon's Expectations
GlobalData, Nov 2011, Pages: 5
Provenge fails to Live up to Dendreon’s Expectations
Summary
GlobalData, the industry analysis specialist, has released its new report, “Provenge fails to Live up to Dendreon’s Expectations”. The report is an essential source of information and analysis on Provcenge failure in prostate cancer therapeutics market. The report provides insights on the failure of provange and its downturn in the prostate cancer market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the prostate cancer market. Its scope includes -
- Provenge failure in prostate cancer market
- Understanding of upcoming strategies by Dendreon to maintain a hold in the market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Drive revenues by understanding the lessons to be learned from the developmental and commercial hurdles faced by Provenge after its approval.
|
|
|
|
